Instinct Bio Files Form 20-F Shell Company Report With the U.S. Securities and Exchange Commission
Comprehensive disclosure of the Company's structure, capitalization and operations following its Nasdaq listing under the ticker BIOT.
Key Facts
- Company
- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
- Ticker
- Nasdaq: BIOT
- Announcement Date
- Category
- IR
- Source
- Official BIOT announcement
TOKYO, JAPAN – July 29, 2026
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") announced that on July 29, 2026 it filed a Shell Company Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key points
Date of event requiring the report: July 23, 2026, the closing of the business combination with Relativity Acquisition Corp.
Registered securities: ordinary shares, par value $0.00001 per share (ticker: BIOT), and warrants, each exercisable for one ordinary share at an exercise price of $11.50 (ticker: BIOTW), both listed on The Nasdaq Stock Market LLC.
Shares outstanding: 28,794,472 ordinary shares as of July 23, 2026.
Jurisdiction: Cayman Islands, with principal executive offices in Shinagawa-ku, Tokyo, Japan.
The report provides comprehensive disclosure of the Company's business, risk factors, management, major shareholders and capital structure, related party transactions and financial information. Investors should review the complete filing on SEC EDGAR.
Original filing (SEC EDGAR):
https://www.sec.gov/Archives/edgar/data/2072188/000110465926087649/tm2621369d1_20f.htm
The Company also furnished a Report on Form 6-K on July 30, 2026, attaching its July 29, 2026 press release regarding the planned launch of GENRÊVER CLINIC in Indonesia.
https://www.sec.gov/Archives/edgar/data/2072188/000110465926088487/tm2621671d1_6k.htm
Source Documents
Follow @BIOT_jp on X for company news and published IR updates.
